BIO International Convention
When the stakes are this high, we can’t go it alone. BIO unites a global network of business leaders, policymakers, investors and scientists for a common purpose: curing patients, protecting the planet, and nourishing humanity. Whether it’s across hemispheres or across the aisle, BIO brings the industry together to solve the most pressing issues facing our world.
Find potential business partners and request meetings through our easy-to-use online system. You can expect to find senior biotech executives, business development leaders, and investors from premier firms participating.
Innovative programming around the current and future state of biotech. Including areas like therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital.
Elevate your company's presence while at BIO 2024.
Compete with other early stage start-ups for a chance to win BIO's Start-Up Stadium competition.
BIO's Phyllis Arthur discusses the inherent need to explore the policies and political will needed to make adult immunization a standard of care globally.
FDA Commissioner Dr. Robert Califf will discuss the latest issues at the FDA, the use of technology in medicine, and the challenges presented by misinformation in a wide-ranging interview with Rachel King, CEO, BIO.
Michelle Wu announces Boston's Life Sciences Workforce Initiative and how the city is empowering residents to gain access to all aspects of the Life Sciences sector.
Hear from various attendees at BIO 2023 on the amazing networking opportunities during the week.
Katie Couric as she shares her work with Stand Up to Cancer in an exclusive interview with Rachel King, CEO, BIO.
Marcel van Duin discusses new innovation for women in the pipeline, and more companies are paying attention to, and investing in, women’s health.
Catch a preview of the series of inspirational short films highlighting patient stories and biotech innovators.
Emma Wheatley discusses strategic plans to encourage vaccine manufacturing in Africa, the commitments made, the challenges experienced and the opportunities available for collaboration and finding new solutions.
Key opinion leaders in the EU discuss a new mandatory system for assessing the clinical value of new products for the European market.
